Tanshinone IIA Reverses Oxaliplatin Resistance In Human Colorectal Cancer Via Inhibition Of ERK/Akt Signaling Pathway

BACKGROUND: Oxaliplatin (OXA)-based chemotherapy is generally used to treat human cancers, whereas OXA resistance is a main obstacle for the treatment of colorectal cancer (CRC). Evidence has shown that tanshinone IIA (Tan IIA) could induce apoptosis in CRC cells. However, the role of combination of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Zhang, Yonggang, Ge, Tingrui, Xiang, Ping, Zhou, Jingyi, Tang, Shumin, Mao, Haibing, Tang, Qiang
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2019
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6859961/
https://ncbi.nlm.nih.gov/pubmed/32009805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S217914
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky